The role of lipids in CVD prevention: Lessons learned about statins
Clinical updates in management of cardiovascular risk (2/4)
For lowering LDL-c, statins play a major role in both primary and secondary CV prevention in all patients. There is room for improvement with respect to choosing the right dosing regimen.
Video navigation menu
- Statins in primary prevention 00:48
- Intensity of statin therapies used in secondary prevention 02:57
- Do all patients benefit from statins? 05:51
- Do statins lower CVD risk in CKD? 07:05
- Statins and CKD: One size fits all? 09:22
This educational video is part of a series of 4 videos with the theme: Clinical Updates in Management of Cardiovascular Risk.
Educational objectives are:
- To review the epidemiology and current guidelines on the diagnosis, management, and treatment of patients at increased CV risk
- To understand the medical need for intensive risk interventions in patients at high CV risk, including diabetes
- To discuss new concepts in cardiovascular risk management including earlier and more intensive intervention and integrate scientific evidence from key clinical trials into practice
- To explore the role of new risk calculation models for cardiovascular risk estimation and communication
Professor Kees Hovingh, MD - Internist and vascular medicine specialist at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, the Netherlands and
visiting professor at Imperial college in London, UK
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding for this educational program was provided by an unrestricted educational grant from Pfizer
This is available as accredited online CME for members. Click the button below to enroll:Enroll